Note 3 Supplemental Financial Information

Interest Expense, Net

years ended December 31 (in millions)	2015			2014			2013

Interest expense	$	719		$	429		$	299
Interest income		(33	)		(38	)		(21	)

Interest expense, net	$	686		$	391		$	278

Interest expense, net in 2015 included $86 million of bridge financing-related costs incurred in connection with the acquisition of Pharmacyclics. Refer to Note 5 for additional information. Interest expense, net in 2014 included $141 million of financing related fees incurred in connection with the terminated proposed combination with Shire plc, a company incorporated in Jersey (Shire).

Other Expense (Income), Net

Other expense (income), net, includes income or expense from the resolution of certain contractual agreements, impairments of equity securities, and gains and losses on the sale of equity securities. Other expense, net in 2015 primarily consisted of impairments of certain equity securities. Other income, net in 2014 primarily consisted of income of $34 million from the resolution of a contractual agreement.

Accounts Payable and Accrued Liabilities

as of December 31 (in millions)	2015		2014

Sales rebates	$	2,355	$	1,384
Accounts payable		1,597		1,401
Dividends payable		924		791
Salaries, wages and commissions		632		623
Royalty and license arrangements		411		821
Other		2,544		1,934

Accounts payable and accrued liabilities	$	8,463	$	6,954

Other Long-Term Liabilities

as of December 31 (in millions)	2015		2014

Pension and other post-employment benefits	$	1,949	$	2,220
Liabilities for unrecognized tax benefits		902		471
Other		844		990

Other long-term liabilities	$	3,695	$	3,681